抗HCV是否步入以DAA为主的特异性治疗时代?

Anti-HCV therapy:Whether it comes into the age of DAAbased specific therapy?

丙型肝炎病毒(hepatitis C virus,HCV)感染是导致慢性肝脏疾病的原因之一.直接抗病毒(direct-acting antiviral,DAA)药物的问世无疑给不能耐受或不适合干扰素治疗的患者带来了希望.2014-2015年国外已经发布了6部关于抗HCV治疗的指南,而2015-10我国也更新了HCV感染的诊治的指南.本文对抗HCV的治疗现状及趋势作一简要概述.

Hepatitis C virus（HCV） infection is one of the main causes of chronic liver diseases.Directacting antiviral（DAA） agents undoubtedly bring hope for patients who cannot tolerate or are not suitable for interferon therapy.There have been six foreign guidelines for anti-HCV therapy in 2014,and in October this year,China also updated its guideline for the diagnosis and treatment of HCV infection.In this paper I review the current status and future perspectives of HCV treatment.